THERAPY DOSSIER · th-0d2b31ee1d45

Poly(d,l-lactic-co-glycolic acid) (PLGA) scaffold of low/soft or high/hard rigidity carrying adult human bone marrow mesenchymal stromal stem cells

Device · PLGA scaffold (soft/hard) carrying human bone-marrow MSCs; cell-biomaterial construct.

Evidence & regulatory context

Mechanism: PLGA scaffold (soft/hard) carrying human bone-marrow MSCs; cell-biomaterial construct.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31229638 ↗2019Mixed findings

Physical impacts of PLGA scaffolding on hMSCs: Recovery neurobiology insight for implant design to treat spinal cord injury.

RatSpinal cord injuryHemisection / partialSprague-DawleyFemaleTransplantation into the lesion epicentreImplanted at the time of acute hemisection injury

Model: Acute T9-10 segmental hemisection spinal cord injury

Only soft PLGA-scaffolded human mesenchymal stromal cells improved sensorimotor function, reduced neuroinflammation and protected tissue, whereas hard-rigidity PLGA drove mesoderm differentiation with ectopic bone, cartilage and muscle markers in neural parenchyma.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…